Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and failing to account for rising customer acquisition costs, leading to a significant drop in share value [1][3]. Company Overview - LifeMD, Inc. is a direct-to-consumer telehealth company based in New York, providing virtual healthcare services and pharmacy offerings in areas such as men's health, obesity treatment, and chronic care [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025, with a deadline of October 27, 2025, for investors to seek lead plaintiff status [1][2]. - The complaint claims that LifeMD raised its 2025 guidance recklessly, which contributed to the misrepresentation of its financial health [3]. Financial Impact - Following the revelation of the company's financial issues, LifeMD shares experienced a dramatic decline, losing 44% of their value in a single trading session [3].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, due to alleged misleading statements and failure to disclose critical information regarding the company's competitive position and customer acquisition costs [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that LifeMD's defendants made materially false and misleading statements about the company's business and operations, particularly overstating its competitive position and inadequately accounting for rising customer acquisition costs [5]. - Investors who purchased LifeMD securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by October 27, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all persons or entities who purchased or otherwise acquired LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) securities between May 7, 2025 and August 5, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or misleading statements and/or failed t ...

Core Viewpoint - The complaint against LifeMD alleges that the company and its executives violated federal securities laws by making misleading statements and failing to disclose critical information regarding their competitive position and customer acquisition costs [2]. Financial Performance - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from the previous guidance of $268 to $275 million [3]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [3]. Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [4]. - The law firm Faruqi & Faruqi encourages individuals with information regarding LifeMD's conduct to come forward, including whistleblowers and former employees [5].

ATLANTA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) Defendants materially overstated LifeMD’s competitive position and (2) Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against LifeMD, Inc. following disappointing Q2 2025 financial results and a reduced outlook, which was raised just three months prior [1][5]. Group 1: Lawsuit Details - The lawsuit seeks to represent investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025 [1]. - The lead plaintiff deadline for the lawsuit is set for October 27, 2025 [3]. - The litigation focuses on LifeMD's statements made on May 6, 2025, when the company reported its Q1 2025 financial results and raised its full-year 2025 revenue and adjusted EBITDA guidance [3]. Group 2: Financial Performance and Guidance - LifeMD raised its guidance in May 2025, citing the creation of a competitive moat in virtual obesity care and strong performance from its RexMD brand [4]. - The company later reported Q2 2025 results that missed consensus estimates, reducing revenue guidance by approximately 6.7% to 7.3% and slashing adjusted EBITDA guidance by about 12% to 13% [5][6]. - The disappointing results were attributed to higher-than-anticipated refund rates and elevated customer acquisition costs in the competitive ED market [6]. Group 3: Investigation and Claims - Hagens Berman, a national shareholders rights firm, has opened an investigation into whether LifeMD violated securities laws [2][7]. - The investigation is focused on whether LifeMD recklessly guided on May 6, 2025, while facing challenges in its weight management and RexMD segments [7]. - The complaint alleges that LifeMD made false and misleading statements and failed to disclose crucial information while insiders sold significant amounts of their shares [4].

Core Viewpoint - LifeMD, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and increased customer acquisition costs [1][3]. Financial Performance - On August 5, 2025, LifeMD reported its second quarter 2025 results, indicating that customer acquisition costs rose by 5% to 25% compared to the previous quarter, impacting the business negatively [3]. - The company's transition into the weight management space was highlighted as a significant factor in the increased costs, with analysts suggesting that management lost focus on customer acquisition for its RexMD platform [3]. Stock Market Reaction - Following the announcement of the second quarter results, LifeMD's stock price experienced a significant decline, falling by $5.31 per share, or 44.84%, closing at $6.53 per share on August 6, 2025 [4].

While LifeMD (NASDAQ: LFMD ) continues to record strong growth from its telehealth platforms, dual misses for its fiscal 2025 second quarter have led investors to revise previous estimates for growth downwards. I'm more neutral on the commons The equity market is a powerful mechanism as daily fluctuations in price get aggregated to incredible wealth creation or destruction over the long term. Pacifica Yield aims to pursue long-term wealth creation with a focus on undervalued yet high-growth companies, high- ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of LifeMD, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased LifeMD securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to LifeMD [2]. Group 2: Financial Results and Stock Impact - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance from a previous range of $268 to $275 million down to $250 to $255 million [3]. - Following the announcement of the revised guidance, LifeMD's stock price dropped by 44.8% on August 6, 2025 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered over $438 million for investors in 2019 alone [4].

Investors can contact the law firm at no cost to learn more about recovering their losses Following this announcement, LifeMD's stock price declined sharply, falling 44.8% on August 6, 2025. LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises LifeMD, Inc. ("LifeMD" or "the Company") (NASDAQ: LFMD) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. LifeMD investors that lost money on their investmen ...